RVU Stock Overview
A clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ryvu Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł52.00 |
| 52 Week High | zł72.40 |
| 52 Week Low | zł47.00 |
| Beta | 0.60 |
| 11 Month Change | -0.95% |
| 3 Month Change | -4.94% |
| 1 Year Change | -7.31% |
| 33 Year Change | -15.45% |
| 5 Year Change | -10.34% |
| Change since IPO | 862.96% |
Recent News & Updates
Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Shareholder Returns
| RVU | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -2.8% | -0.8% | -0.7% |
| 1Y | -7.3% | -6.8% | 16.7% |
Return vs Industry: RVU matched the Polish Life Sciences industry which returned -6.8% over the past year.
Return vs Market: RVU underperformed the Polish Market which returned 16.7% over the past year.
Price Volatility
| RVU volatility | |
|---|---|
| RVU Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.3% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: RVU has not had significant price volatility in the past 3 months.
Volatility Over Time: RVU's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 270 | Pawel Przewiezlikowski | www.ryvu.com |
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
Ryvu Therapeutics S.A. Fundamentals Summary
| RVU fundamental statistics | |
|---|---|
| Market cap | zł1.20b |
| Earnings (TTM) | -zł93.91m |
| Revenue (TTM) | zł74.41m |
16.2x
P/S Ratio-12.8x
P/E RatioIs RVU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVU income statement (TTM) | |
|---|---|
| Revenue | zł74.41m |
| Cost of Revenue | zł17.49m |
| Gross Profit | zł56.91m |
| Other Expenses | zł150.83m |
| Earnings | -zł93.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 11, 2024
| Earnings per share (EPS) | -4.06 |
| Gross Margin | 76.49% |
| Net Profit Margin | -126.22% |
| Debt/Equity Ratio | 45.3% |
How did RVU perform over the long term?
See historical performance and comparison